Japan’s pharmaceutical sector is gradually reorienting from deep, validation-led development towards execution-driven partnerships, as global pressure compresses timelines across drug development.

AbbVie’s ultra-rare blood cancer ADC secured FDA clearance while AstraZeneca’s oral SERD for breast cancer remains in regulatory limbo.

Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical pipeline.

The US biotech’s technology integrates multiple protein modalities to simultaneously target a variety of disease mechanisms.

SK bioscience has signed a vaccine technology transfer and manufacturing deal with VECOL, becoming part of Colombia’s $260m vaccine localisation initiative.

Autobahn Therapeutics has received fast track designation from the FDA for elunetirom, its lead CNS-directed thyroid hormone receptor agonist.

Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.

The HAE pharmaceutical landscape is set for unprecedented expansion as a large proportion of pipeline drugs are found in Phase III.

AstraZeneca and Daiichi Sankyo have secured approval from the US FDA for Datroway (datopotamab deruxtecan) to treat metastatic TNBC.

Takeda has been ordered to pay $885m – potentially rising to $2.5bn – after a landmark court case verdict found the Japanese pharma company liable for a conspired arrangement ...

Bristol Myers Squibb (BMS) has signed a strategic agreement with Anthropic to implement its Claude platform across its global operations.

The new healthcare firm will operate across the North American, APAC and European markets, which make up around 90% of the global R&D spend.